Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,116 recruiting studies in this area right now.
By phase
- Not applicable9,488
- Phase 24,391
- Phase 12,658
- Phase 1/Phase 21,647
- Phase 31,391
- Phase 2/Phase 3281
- Phase 4260
Top conditions
- Breast Cancer1,192
- Prostate Cancer644
- Cancer632
- Colorectal Cancer478
- Lung Cancer415
- Ovarian Cancer336
- Multiple Myeloma328
- Pancreatic Cancer287
- Gastric Cancer283
- Acute Myeloid Leukemia279
- Hepatocellular Carcinoma256
- Solid Tumor245
- Advanced Solid Tumor235
- Head and Neck Cancer225
- Cervical Cancer223
- Endometrial Cancer206
- Advanced Solid Tumors199
- Esophageal Cancer189
Leading sponsors
- M.D. Anderson Cancer Center453
- Fudan University303
- National Cancer Institute (NCI)292
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University273
- Mayo Clinic237
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences140
- City of Hope Medical Center140
- AstraZeneca134
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,404
- Texas636
- Arizona513
- Florida431
- Alabama424
- New York407
- Massachusetts340
- Maryland332
- New Jersey269
- Pennsylvania234
Recruiting studies20,116 total
- NCT05839275RecruitingPhase 1/Phase 2
Radiation plus two medicines for high-risk soft tissue sarcoma
This Phase 1/2 trial tests whether combining radiation with two targeted/immune medicines can shrink or control high-risk soft tissue sarcoma and improve outcomes. It may help patients whose tumors are large, hard to fully remove, or have come back after prior treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05994365Recruiting
Testing anlotinib for advanced thyroid cancer that resists radioactive iodine
This trial tests a targeted therapy pill (anlotinib) for people with advanced thyroid cancer that stopped responding to radioactive iodine. It may slow tumor growth or shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT06000917RecruitingPhase 2
Study of combination therapy before surgery for ER+/HER2+ breast cancer
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
Wuhan, HubeiAges 18–75 - NCT03637569Recruiting
Skinfold fat measurement and survival in certain digestive cancers
This study looks at whether a simple measurement of fat under the skin (taken at the back of the upper arm) relates to how long people live. It includes adults newly diagnosed with pancreatic, bile duct, or gallbladder cancer who are starting treatment.
SeoulAges 18 years+ - NCT01885767Recruiting
Neurofibromatosis registry for NF1, NF2, and Schwannomatosis
This trial is a patient registry portal for people diagnosed with neurofibromatosis types NF1, NF2, or schwannomatosis. By joining, you help researchers collect real-world information that may guide future studies and care.
New York, New YorkAges Any age - NCT06001619RecruitingPhase 4
Prostate medication, metabolism, and gut bacteria
This study looks at how prostate medication affects your metabolism and the helpful bacteria in your gut. It may help explain how these drugs work and how they affect your body.
TurkuAges 18 years+ - NCT05879783Recruiting
Optical biopsy during surgery for colorectal belly tumors
This trial looks at using a special light-based method (optical biopsy) to examine small growths on the lining of the abdomen during colorectal cancer surgery. It may help doctors better assess these peritoneal nodules while you are already having an operation.
Guangzhou, GuangdongAges 18–85 - NCT06006650RecruitingPhase 2
Neoadjuvant therapy for stage II-IVA esophageal cancer
This trial tests a treatment given before surgery for patients with a type of esophageal cancer called squamous cell carcinoma, stages II to IVA. The goal is to see if this approach can improve outcomes.
Xi'an, ShaanxiAges 18–75 - NCT05502198Recruiting
How muscle loss matters in advanced liver disease
This study looks at how loss of muscle strength or mass (sarcopenia) relates to advanced liver disease. It may help doctors understand which patients are at higher risk and could guide future care choices.
EksjöAges 18 years+ - NCT05871762Recruiting
Choosing best treatment plans for mid-to-low rectal cancer
This trial studies how to choose the best treatment strategy for people with rectal cancer located in the middle to lower part of the rectum. It may help doctors match the right treatment plan to tumor location and your overall situation.
Beijing, Beijing MunicipalityAges Any age - NCT05631886RecruitingPhase 1
Testing a cancer vaccine plus immune therapy for hard tumors
This early-phase trial tests whether combining a lab-made CAR-DC cancer vaccine with immune checkpoint medicines can shrink tumors that have specific genetic changes. It’s meant for people with advanced or returning (relapsed) solid tumors or certain lymphomas that match required tumor markers.
Beijing, Beijing MunicipalityAges 18–75 - NCT05956847Recruiting
Studying DNA fragments in stomach cancer tissue
This trial looks at tiny pieces of DNA found outside cells in stomach tissue to better understand how gastric (stomach) cancer starts and progresses. It may help future patients by improving how doctors study stomach cancer from biopsy and surgical samples.
Xi'an, ShaanxiAges 18–80 - NCT05336539Recruiting
Community screening study for colorectal cancer using methylation testing
This study recruits adults in Yangzhou to help screen for colorectal cancer risk using a lab test based on “methylation,” a way cells can carry disease-related changes. You would mainly complete a risk questionnaire and phone follow-ups, and agree to share any cancer diagnosis information during the study.
Yangzhou, JiangsuAges 40–74 - NCT06015802Recruiting
Predicting pituitary tumor behavior with markers and scans
This study looks at whether blood and tissue markers, along with imaging features, can predict how aggressive a pituitary neuroendocrine tumor is and how it may affect long-term health. It aims to improve treatment decisions by better understanding these tumors.
Guangzhou, GuangdongAges 18–70 - NCT05047510Recruiting
Fluorescent-guided surgery for liver cancer using GPC3 dye
This trial studies whether a special fluorescent dye that targets GPC3 can help surgeons find liver cancer more clearly during an operation. It may improve how accurately tumor tissue is identified while you have surgery for hepatocellular carcinoma.
Zhuhai, GuangdongAges 18–75 - NCT05644431Recruiting
Study of immune environment in operable stomach cancer
This study looks at how the immune system behaves in stomach or lower esophagus cancer before standard (planned) surgery. It may help researchers understand which immune features relate to outcomes and treatment response.
LyonAges 18 years+ - NCT03127761Recruiting
Transplant study for Medicare patients with advanced myeloma
This study looks at outcomes of an allogeneic transplant (a donor-based transplant) in people with stage II–III multiple myeloma or primary plasma cell leukemia who have Medicare. It may help doctors better understand which patients benefit and what to expect before and after transplant.
Minneapolis, MinnesotaAges Any age - NCT06026774RecruitingPhase 1
Personalized mRNA Vaccine After Digestive Cancer Surgery
This trial tests a personalized mRNA vaccine designed to train your immune system to fight your specific cancer. It's for people who have just had surgery to remove a digestive system cancer (like pancreatic or colorectal) and will also receive standard chemotherapy after surgery.
Hangzhou, ZhejiangAges 18–75 - NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT05600127RecruitingPhase 2
Chemotherapy then immunotherapy plus surgery for advanced bladder cancer
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
Nijmegen, GelderlandAges 18 years+ - NCT04728724RecruitingPhase 2
Check immune treatment before surgery for stage III lung cancer
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
ShanghaiAges 18–75 - NCT05378087Recruiting
Compare two ways to plan treatment for cervical cancer
This study compares two staging methods—using surgery results versus imaging tests—to help doctors plan treatment for locally advanced cervical cancer. It may improve how accurately the cancer is mapped, which could affect treatment choices and outcomes.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05009927RecruitingPhase 2
Check whether continuing imatinib works after long GIST control
This trial studies people with advanced or metastatic gastrointestinal stromal tumor (GIST) who have been on the drug imatinib for 10 years with stable, non-growing disease. The goal is to see how effective it is to keep imatinib going after this long period.
BesançonAges 18 years+ - NCT05962502RecruitingPhase 2
Cetuximab plus irinotecan for left-sided RAS/BRAF wild-type colon cancer
This Phase 2 trial tests whether adding cetuximab to irinotecan can control metastatic colorectal cancer that has returned or worsened after standard treatments. It targets people whose tumor is left-sided and shows “wild-type” RAS and BRAF genes on blood testing after prior therapy.
Guangzhou, GuangdongAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,116 recruiting oncology studies from the U.S. registry right now, out of 29,780 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.